Navigation Links
Adult COPD or asthma could be effectively treated with Xopenex

COPD - Chronic Obstructive Pulmonary Disease - including chronic bronchitis and emphysema, is characterized by breathing difficulty due to partial blockage of the bronchial tubes. Asthma is a chronic lung disease caused by inflammation of the lower airways resulting in episodes of airflow obstruction, which has been found to be the fourth most common// cause of death and affects nearly 16 million people in the United States. According to the American Lung Association, it is the most common childhood illness and affects approximately 8.6 million children under the age of 18.

A new study conducted at the Halifax Regional Hospital in South Boston, suggested Xopenex as a viable first-line therapy for hospitalized adult COPD or asthma patients. Lead author of the study, Terrance Truitt said that Xopenex is safe in a hospital setting, and is an effective alternative to racemic albuterol in treating the bronchial smooth muscle spasm associated with diseases such as COPD and asthma. The study involved the comparison of the treatment of 231 patients with similar background and disease conditions over two separate six-month periods. The first group had been treated with the previous standard treatment, the second group with Xopenex. It was found that the subjects showed significant symptom improvement and a change in the frequency of nebulizer treatments - in intervals of 6 to 8 hours. This change was achieved with a 1.25 mg dose of Xopenex. In addition, the Xopenex group needed only 2.0 +/- 2.6 days of ipratropium bromide treatments. Patients receiving Xopenex were found to require significantly less nebulizer therapy and less adjuvant respiratory therapy, according to the study.

Xopenex is being marketed as a nebulizer at dosage strengths of 0.31 mg and 0.63 mg for pediatric patients and as 0.63 mg and 1.25 mg for patients 12 years of age and older. Xopenex brand levalbuterol HCl inhalation solution is indicated for the treatment or prevention of bronc hospasm in patients 6 years and older with reversible obstructive airway disease, such as asthma.


'"/>




Related medicine news :

1. Baby Talk Better Than Adult Speech
2. A question on study of Adult Stem Cell
3. Adult stem cells in treatment for Multiple sclerosis (MS)
4. The Key To Prevention Of Heart Disease In Adults
5. The Harmful Effects Of Stress in Young Adults
6. Abuse in Childhood Could Result In Heart Disease in Adulthood
7. Adult bone health is dependent on lifestyle we live
8. Adult Stem Cells From Fat Tissues For Healing
9. Obese Adults Undergo Less Medical Tests And More Vulnerable To Diseases
10. A New Technique For Prediction Of Adult Height
11. New Drug Found To Improve Driving Performance In Young Adults With ADHD
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology: